SWTX SpringWorks Therapeutics, Inc.

Springworks Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company. It identifies pathways for drug development for patients with severe rare diseases and cancer. The firm's products include Nirogacestat, Mirdametinib and BGB-3245. The company was founded in August 2017 and is headquartered in Stamford, CT.

$27.75  +0.72 (2.66%)
As of 10/04/2022 13:26:23 EST     IEX book   CBOE book

---

Security Information

---

Category1:  US Equity
Category2:  Common stocks
Category3:  Small cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  01/04/1999
Outstanding shares:  62,401,071
Average volume:  1,055,139
Market cap:   $1,780,302,556
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BGMGM89

---

Valuation   (See tab for details)

---

PE ratio:   -16.40
PB ratio:   3.51
PS ratio:   356.05
Return on equity:   -54.65%
Net income %:   -4,118.38%